Related references
Note: Only part of the references are listed.The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling
Oncotarget (2015)
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer
Roland H. Stauber et al.
Oncotarget (2015)
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
H. K. Kim et al.
PHARMACOGENOMICS JOURNAL (2012)
Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Leo Kretzner et al.
CANCER RESEARCH (2011)
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
Victoria L. Luchenko et al.
CELL CYCLE (2011)
The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
P. N. Kelly et al.
CELL DEATH AND DIFFERENTIATION (2011)
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K. Ted Thurn et al.
FUTURE ONCOLOGY (2011)
A Simple and Cost-Effective Method to Transfect Small Interfering RNAs Into Pancreatic Cancer Cell Lines Using Polyethylenimine
Matthias Wirth et al.
PANCREAS (2011)
A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients
Hark Kyun Kim et al.
PLOS ONE (2011)
c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance
Slovenie Pyndiah et al.
SCIENCE SIGNALING (2011)
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer
Kathrin Mutze et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors
Prashant V. Bommi et al.
CELL CYCLE (2010)
Inhibitors of HDACs - Effective Drugs Against Cancer?
S. Mueller et al.
CURRENT CANCER DRUG TARGETS (2010)
The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy
Lars-Gunnar Larsson et al.
EXPERIMENTAL CELL RESEARCH (2010)
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Paul A. Marks
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner et al.
Clinical Epigenetics (2010)
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
CANCER LETTERS (2009)
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Ailsa J. Frew et al.
CANCER LETTERS (2009)
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Nahum Sonenberg et al.
CELL (2009)
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
P. Fritsche et al.
GUT (2009)
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Anchit Khanna et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Targeting the eukaryotic translation initiation factor 4E for cancer therapy
Jeremy R. Graff et al.
CANCER RESEARCH (2008)
c-Myc and eIF4F are components of a feedforward loop that links transcription and translation
Chen-Ju Lin et al.
CANCER RESEARCH (2008)
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling
Alpana Soni et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells
S. Inoue et al.
LEUKEMIA (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
Chromatin immunoprecipitation (ChIP) coupled to detection by quantitative real-time PCR to study transcription factor binding to DNA in Caenorhabditis elegans
Arnab Mukhopadhyay et al.
NATURE PROTOCOLS (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
MYC and gastric adenocarcinoma carcinogenesis
Danielle Queiroz Calcagno et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment
Canhua Huang et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells
Volker Wacheck et al.
CANCER BIOLOGY & THERAPY (2006)
Increased expression of historic deacetylase 2 is found in human gastric cancer
J Song et al.
APMIS (2005)
Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome
CN Chen et al.
JOURNAL OF SURGICAL ONCOLOGY (2004)
Low molecular weight inhibitors of Myc-Max interaction and function
XY Yin et al.
ONCOGENE (2003)
Genomic targets of the human c-Myc protein
PC Fernandez et al.
GENES & DEVELOPMENT (2003)
Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression
S Skov et al.
BLOOD (2003)
Expression profile of histone deacetylase 1 in gastric cancer tissues
JH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Molecular therapy with recombinant antisense c-myc adenovirus for human gastric carcinoma cells in vitro and in vivo
JP Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2001)
Share Paper
